Overcoming Barriers to Use of SGLT2 Inhibitor Therapy-Reference-Cited by-同舟云学术

Overcoming Barriers to Use of SGLT2 Inhibitor Therapy

Published:2023-08 Issue:8 Volume:11 Page:943-945
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Greene Stephen J.,Pierce Jacob B.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference6 articles.

1. Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US;Talha;JAMA Cardiol,2023

2. Evaluation of quality of care for US veterans with recent-onset heart failure with reduced ejection fraction;Sandhu;JAMA Cardiol,2022

3. Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure;Faridi;J Am Coll Cardiol,2022

4. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry;Greene;J Am Coll Cardiol,2018

5. Utilization rates of SGLT2 inhibitors among patients with type 2 diabetes, heart failure, and atherosclerotic cardiovascular disease;Hussain;J Am Coll Cardiol HF,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why do clinicians not prescribe quadruple medical therapy for heart failure with reduced ejection fraction?;European Journal of Heart Failure;2024-01-18

2. Safety of sodium‐glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta‐analysis;ESC Heart Failure;2023-12-20

3. Implementation of sodium–glucose cotransporter 2 inhibitors for heart failure with reduced ejection fraction: Where we are versus where we need to be;European Journal of Heart Failure;2023-08-22